Previous Close | 3.4200 |
Open | 3.4400 |
Bid | 3.3300 x 1100 |
Ask | 3.3700 x 1000 |
Day's Range | 3.1400 - 3.4550 |
52 Week Range | 2.6200 - 26.7000 |
Volume | |
Avg. Volume | 700,088 |
Market Cap | 132.717M |
Beta (5Y Monthly) | 2.18 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.3050 |
Earnings Date | Mar 21, 2022 - Mar 25, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.00 |
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Dominic Piscitelli, chief financial officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7:00 a.m. ET. The pre-recorded presentation will be available through the investor s
Those following along with ORIC Pharmaceuticals, Inc. ( NASDAQ:ORIC ) will no doubt be intrigued by the recent purchase...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented three preclinical poster presentations and one preclinical oral presentation at the 2022 American Cancer Research Association (AACR) Annual Meeting. “Our four presentations at AACR reflect the broad and diverse pipeline of differentiated programs at O